Error message

  • Warning: include_once(): Unable to allocate memory for pool. in drupal_settings_initialize() (line 716 of /var/www/html/nia/includes/bootstrap.inc).
  • Warning: require_once(): Unable to allocate memory for pool. in _drupal_bootstrap_page_cache() (line 2366 of /var/www/html/nia/includes/bootstrap.inc).
  • Warning: require_once(): Unable to allocate memory for pool. in _drupal_bootstrap_page_cache() (line 2368 of /var/www/html/nia/includes/bootstrap.inc).
  • Warning: require_once(): Unable to allocate memory for pool. in _drupal_bootstrap_database() (line 2456 of /var/www/html/nia/includes/bootstrap.inc).
  • Warning: require_once(): Unable to allocate memory for pool. in _drupal_bootstrap_variables() (line 2473 of /var/www/html/nia/includes/bootstrap.inc).
  • Warning: require_once(): Unable to allocate memory for pool. in Database::openConnection() (line 1685 of /var/www/html/nia/includes/database/database.inc).
Alzheimer's Disease Education and Referral Center

AAB-003 (PF-05236812) in Alzheimer's Disease

AAB-003 (PF-05236812) in Alzheimer's Disease

Overall Status: 
Completed
Brief Description: 

This Phase I study will evaluate the safety of the experimental drug AAB-003 (PF-05236812) in people with mild to moderate Alzheimer's disease. Participants will receive one of five doses of AAB-003 or a placebo. Participation will last approximately 41 weeks.

Patient Qualifications: 
Min AgeMax AgeGenderHealthy Volunteers
50 Years
89 Years
Both
No
Inclusion Criteria: 

  • Diagnosis of probable Alzheimer's dsease (MMSE score of 16-26 and brain MRI consistent with Alzheimer's)
  • Use of cholinesterase inhibitor or memantine allowed, if stable
  • Availability of caregiver to attend clinic visits with participant

Exclusion Criteria: 

  • Significant neurological disease other than Alzheimer's disease
  • Major psychiatric disorder
  • Contraindication to brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
  • Women of childbearing potential

Detailed Description: 

None given.

Central Contact Information: 

For more information about this clinical trial, please contact the Pfizer CT.gov Call Center at 1-800-718-1021.

Locations: 
Map Marker CityStateZip CodeStatusPrimary Contact

Geolocation is 33.090285, -117.0499859

Site
Escondido
California
92025
Name:
Phone:

Geolocation is 25.9812024, -80.148379

Site
Hallandale Beach
Florida
33009
Name:
Phone:

Geolocation is 29.1571921, -82.1223977

Site
Ocala
Florida
34471
Name:
Phone:

Geolocation is 29.1259294, -82.2800546

Site
Ocala
Florida
34481
Name:
Phone:

Geolocation is 33.7717008, -84.3726049

Site
Atlanta
Georgia
30308
Name:
Phone:

Geolocation is 39.0038878, -77.1053673

Site
Bethesda
Maryland
20814
Name:
Phone:

Geolocation is 39.0839973, -77.1527578

Site
Rockville
Maryland
20850
Name:
Phone:

Geolocation is 42.2917069, -85.5872286

Site
Kalamazoo
Michigan
49048
Name:
Phone:

Geolocation is 32.3095903, -90.1389757

Site
Flowood
Mississippi
39232
Name:
Phone:

Geolocation is 38.6608855, -90.422618

Site
Creve Coeur
Missouri
63141
Name:
Phone:

Geolocation is 38.767401, -90.4408037

Site
St. Louis
Missouri
63044
Name:
Phone:

Geolocation is 40.2962222, -74.0509725

Site
Eatontown
New Jersey
07724
Name:
Phone:

Geolocation is 40.5230137, -74.3411515

Site
Edison
New Jersey
08837
Name:
Phone:

Geolocation is 40.2613515, -74.023593

Site
Oakhurst
New Jersey
07755
Name:
Phone:

Geolocation is 39.9915379, -75.2187346

Site
Philadelphia
Pennsylvania
19131-1689
Name:
Phone:

Geolocation is 40.0397682, -75.145782

Site
Philadelphia
Pennsylvania
19141
Name:
Phone:
Lead Sponsor: 
Agency
Pfizer
Collaborator Sponsor: 
Agency
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Facility Investigators: 
NameRoleAffiliation
Pfizer CT.gov Call Center
Study Director
Pfizer
Study Contact: 
NamePhone
Pfizer CT.gov Call Center
1-800-718-1021
Locations
 
 
ClinicalTrials.gov ID 
NCT01193608 (follow link to view full record on ct.gov in new window)
Official Title: 
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Study Start Date: 
September 2010
Study End Date: 
October 2013
Disease Stage: 
Early
Middle
Enrollment: 
104